- Home
- VSTE vs BCAB Comparison
VSTE vs BCAB Comparison
Compare VSTE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTE
- BCAB
- Stock Information
- Founded
- VSTE 2009
- BCAB 2007
- Country
- VSTE Australia
- BCAB United States
- Employees
- VSTE N/A
- BCAB N/A
- Industry
- VSTE
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- VSTE
- BCAB Health Care
- Exchange
- VSTE Nasdaq
- BCAB Nasdaq
- Market Cap
- VSTE 30.0M
- BCAB 96.2M
- IPO Year
- VSTE N/A
- BCAB 2020
- Fundamental
- Price
- VSTE $2.42
- BCAB $2.08
- Analyst Decision
- VSTE
- BCAB Strong Buy
- Analyst Count
- VSTE 0
- BCAB 2
- Target Price
- VSTE N/A
- BCAB $6.00
- AVG Volume (30 Days)
- VSTE 14.1K
- BCAB 1.6M
- Earning Date
- VSTE 01-01-0001
- BCAB 11-08-2024
- Dividend Yield
- VSTE N/A
- BCAB N/A
- EPS Growth
- VSTE N/A
- BCAB N/A
- EPS
- VSTE N/A
- BCAB N/A
- Revenue
- VSTE $342,000.00
- BCAB N/A
- Revenue This Year
- VSTE N/A
- BCAB N/A
- Revenue Next Year
- VSTE N/A
- BCAB N/A
- P/E Ratio
- VSTE N/A
- BCAB N/A
- Revenue Growth
- VSTE N/A
- BCAB N/A
- 52 Week Low
- VSTE $0.83
- BCAB $1.14
- 52 Week High
- VSTE $12.00
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- VSTE 55.09
- BCAB 55.80
- Support Level
- VSTE $0.83
- BCAB $1.87
- Resistance Level
- VSTE $1.09
- BCAB $2.13
- Average True Range (ATR)
- VSTE 0.10
- BCAB 0.12
- MACD
- VSTE 0.03
- BCAB 0.00
- Stochastic Oscillator
- VSTE 92.08
- BCAB 68.90
About VSTE Vast Renewables Limited
Vast Renewables Ltd is a clean, renewable energy company specializing in the design and manufacturing of concentrated solar thermal power (CSP) systems to generate carbon-free, utility-scale electricity, industrial heat, and green fuels. The Company's differentiated modular CSP system, utilizing proprietary sodium loop heat transfer technology, provides customers with a solution to the enduring challenge of intermittent renewable energy through 24/7 dispatchable power and heat.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.